PharmaSGP Holding SE (PSG.DE)

EUR 24.8

(4.2%)

EBITDA Summary of PharmaSGP Holding SE

  • PharmaSGP Holding SE's latest annual EBITDA in 2023 was 35.86 Million EUR , up 26.98% from previous year.
  • PharmaSGP Holding SE's latest quarterly EBITDA in 2024 Q2 was 8.98 Million EUR , up 3.8% from previous quarter.
  • PharmaSGP Holding SE reported an annual EBITDA of 27.17 Million EUR in 2022, up 41.33% from previous year.
  • PharmaSGP Holding SE reported an annual EBITDA of 18.49 Million EUR in 2021, up 14.88% from previous year.
  • PharmaSGP Holding SE reported a quarterly EBITDA of 8.98 Million EUR for 2024 Q2, up 3.8% from previous quarter.
  • PharmaSGP Holding SE reported a quarterly EBITDA of 8.62 Million EUR for 2023 Q2, up 18.3% from previous quarter.

Annual EBITDA Chart of PharmaSGP Holding SE (2023 - 2017)

Historical Annual EBITDA of PharmaSGP Holding SE (2023 - 2017)

Year EBITDA EBITDA Growth
2023 35.86 Million EUR 26.98%
2022 27.17 Million EUR 41.33%
2021 18.49 Million EUR 14.88%
2020 14.73 Million EUR -33.32%
2019 22.83 Million EUR 25.69%
2018 19.93 Million EUR 26.77%
2017 15.74 Million EUR 0.0%

Peer EBITDA Comparison of PharmaSGP Holding SE

Name EBITDA EBITDA Difference
MPH Health Care AG 33.31 Million EUR -7.667%
Apontis Pharma AG -12.94 Million EUR 377.159%
Dermapharm Holding SE 277.29 Million EUR 87.065%
Evotec SE 7.82 Million EUR -358.494%
MERCK Kommanditgesellschaft auf Aktien 5.52 Billion EUR 99.35%
SynBiotic SE -7.12 Million EUR 603.58%